The objectives of the study are to 1) Conduct telemetric biosignals (EDA, ECG, and EMG) recording in healthy controls and IBS participants experiencing cutaneous and visceral pain; and 2) Validate the OIME index as a biomarker for quantifying pain in IBS participants and its capability to assess the treatment of IBS pain via an ambulatory trial.
Participants need to be diagnosed with IBS by a healthcare provider according to Rome-III or -IV criteria, with a current report of abdominal pain.
Men and women 18-50 years old
Able to read and speak English
Daily access to a computer with internet access.
Other chronic pains that are usually not comorbid with IBS, e.g., diabetic neuropathy, myofascial pain, low back pain, peripheral neuropathy etc.
Celiac disease or inflammatory bowel disease
Diabetes mellitus; d) Serious mental health conditions
Women during pregnancy or within 3 months post-partum period
University of Connecticut
Lead sponsor
Yale University
Collaborator